title: Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
abstract: Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unresectable tumors can be difficult to manage. Until recently, no approved systemic therapy was available for locally advanced or metastatic BCC inappropriate for surgery or radiotherapy. Vismodegib provides a systemic treatment option. However, a consensus definition of advanced BCC is lacking. A multidisciplinary panel with expertise in oncology, dermatology, dermatologic surgery and radiation oncology proposes a consensus definition based on published evidence and clinical experience.
authors: Department of Dermatology, Catholic University of Rome, Rome, Italy.
authors: Ketty
authors: K
authors: Peris
authors: Lisa
authors: L
authors: Licitra
authors: Paolo A
authors: PA
authors: Ascierto
authors: Renzo
authors: R
authors: Corvò
authors: Marco
authors: M
authors: Simonacci
authors: Franco
authors: F
authors: Picciotto
authors: Giulio
authors: G
authors: Gualdi
authors: Giovanni
authors: G
authors: Pellacani
authors: Armando
authors: A
authors: Santoro
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D003245:Consensus Statements as Topic; D019468:Disease Management; D006801:Humans; D009367:Neoplasm Staging; D011725:Pyridines / Q000627:therapeutic use*; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines
keywords: basal cell carcinoma; locally advanced basal cell carcinoma; therapy; vismodegib